CB Insights today named Atropos Health to its ninth annual AI 100, showcasing the 100 most promising private artificial intelligence companies in the world.
“The AI 100 winners are future movers and shakers, taking big swings that will shape the future of AI,” said Manlio Carrelli, CEO at CB Insights. “This year’s cohort is pushing AI applications from emerging to emerged, working on everything from AI agents for complex processes to security and robotics. They’ve also zeroed in on new and promising technologies that might not be on the radar of many enterprises — multi-agent systems, novel computing and data curation approaches, and physical AI.”
“Atropos Health is proud to be part of the CB Insights AI 100 as we continue to drive the adoption of AI technology into practical use in healthcare and research around evidence generation,” said Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health.
The list recognizes early—and mid-stage startups that are leading the way in applying AI across industries and architectures. Our research team picked winning companies based on CB Insights datasets, including deal activity, industry partnerships, team strength, investor strength, employee headcount, and proprietary Commercial Maturity and Mosaic scores. We also dug into Analyst Briefings submitted directly to us by startups.
In the last year, Atropos Health raised $33 million in Series B funding to scale the automation of high-quality, personalized, real-world evidence. The Atropos Evidence™ Network, the largest federated data network in healthcare, expanded to over 300 million patient records. The company also released ChatRWD®, its generative AI tool which reduces the time to produce high-quality, publication-grade real-world evidence from months to minutes.
With the increasing popularity and adoption of AI in healthcare, Atropos Health is committed to the responsible deployment of technology, ensuring the use of AI meets the highest quality standards required for healthcare. In a published independent study, ChatRWD was compared to other general-purpose and healthcare large language models (LLMs). The study found that ChatRWD outperformed all other LLMs, completing 94 percent of the answers and delivering the best answers for novel questions in 87 percent of the cases. ChatRWD is purpose-built for healthcare and exemplifies Atropos Health’s commitment to quality, accuracy, and transparency in methodology, driving results for stakeholders across the healthcare ecosystem.
Quick facts on the 2025 AI 100:
- The 100 winners include 21 startups in AI agent platforms and infrastructure, 12 in AI observability and governance, and 12 in physical AI technology and building blocks.
- The 2025 cohort is deploying AI across horizontal applications (customer service, process automation), infrastructure (AI observability, AI agent building), and verticals (healthcare and life sciences, industrials, financial services).
- Collectively, these companies have raised $11.4B in equity funding over time, including more than $2.3B in 2025 (as of 4/16/2025).
- Nearly 75% are early-stage companies (Series A or earlier).
- 27 companies are based outside the United States, spanning 13 countries. This includes companies in developing and competitive AI markets like France and South Korea.
- The cohort has formed 315+ business relationships since 2023, including with industry leaders like NVIDIA, Google, and Uber.
About CB Insights
CB Insights is an AI super analyst for market intelligence. It delivers instant insights that help you bet on the right markets, track competitors, and source the right companies. Our AI super analyst is powerful because it is built on the validated database of companies and markets that CB Insights is famous for. To learn more, please visit www.cbinsights.com.
About Atropos Health
Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.
To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424850516/en/
Contacts
CB Insights Contact:
Media@cbinsights.com
Atropos Health Contact:
atropos@solcomms.co